cd 437 has been researched along with efavirenz in 1 studies
Studies (cd 437) | Trials (cd 437) | Recent Studies (post-2010) (cd 437) | Studies (efavirenz) | Trials (efavirenz) | Recent Studies (post-2010) (efavirenz) |
---|---|---|---|---|---|
134 | 0 | 26 | 3,110 | 631 | 1,611 |
Protein | Taxonomy | cd 437 (IC50) | efavirenz (IC50) |
---|---|---|---|
Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain A, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain B, POL POLYPROTEIN | Human immunodeficiency virus 1 | 0.2612 | |
Chain A, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
Chain B, Pol Polyprotein | Human immunodeficiency virus 1 | 0.2612 | |
Prothrombin | Bos taurus (cattle) | 0.022 | |
Gag-Pol polyprotein | HIV-1 M:B_HXB2R | 0.1852 | |
Gag-Pol polyprotein | Human immunodeficiency virus type 1 (NEW YORK-5 ISOLATE) | 0.02 | |
Kappa-type opioid receptor | Cavia porcellus (domestic guinea pig) | 0.018 | |
Microsomal triglyceride transfer protein large subunit | Homo sapiens (human) | 0.054 | |
Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | 0.004 | |
Envelope glycoprotein gp160 [Cleaved into: Surface protein gp120 | Human immunodeficiency virus 1 | 0.0035 | |
Reverse transcriptase/RNaseH | Human immunodeficiency virus 1 | 0.1627 | |
Reverse transcriptase | Human immunodeficiency virus 1 | 0.0643 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ | 1 |
1 other study(ies) available for cd 437 and efavirenz
Article | Year |
---|---|
Identification of potent Yes1 kinase inhibitors using a library screening approach.
Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship | 2013 |